NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
VERU
Veru Inc.
There isn't enough reported data to score VERU yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
VERU Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
VERU's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
VERU PE Valuation
VERU has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
VERU Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect VERU's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over VERU on earnings quality, reporting a profit while its opponent remains loss making.
VERU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.58 | +$1.65 |
| Q1 2026 | -$0.78 | +$1.65 |
| Q4 2025 | -$1.16 | +$1.47 |
| Q3 2025 | -$1.50 | +$1.33 |
| Q2 2025 | -$2.23 | +$0.57 |
| Q1 2025 | -$2.43 | +$0.47 |
| Q4 2024 | -$2.63 | +$4.37 |
| Q3 2024 | -$2.83 | +$7.97 |
VERU is still losing money, but far less than before: $0.58 per share over the past year, against $17.30 at its worst in early 2023.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the stronger quarterly revenue trend. Revenue is up 2.1% for NVO versus down 100% for VERU.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
VERU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2024 | $6.7M | +72% |
| Q2 2024 | $4M | +18% |
| Q1 2024 | $4.1M | -37% |
| Q4 2023 | $2.1M | -15% |
| Q3 2023 | $3.9M | +49% |
| Q2 2023 | $3.3M | -65% |
| Q1 2023 | $6.6M | -49% |
| Q4 2022 | $2.5M | -82% |
VERU's revenue has slid since its 2021 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2024 | -123% | +88 points |
| Q2 2024 | -277% | -41 points |
| Q1 2024 | -239% | +359 points |
| Q4 2023 | -368% | +1051 points |
| Q3 2023 | -212% | +1514 points |
| Q2 2023 | -236% | -8.4 points |
| Q1 2023 | -599% | -508 points |
| Q4 2022 | -1419% | -1384 points |
VERU's operating margin was −123% last quarter, up 88 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over VERU on cash generation, producing positive trailing cash flow while its opponent burns cash.
VERU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$5.5M | +$15.1K |
| Q1 2026 | -$8.9M | -$1.2M |
| Q4 2025 | -$6.2M | +$5.2M |
| Q3 2025 | -$5.5M | -$1.1M |
| Q2 2025 | -$5.5M | +$218.1K |
| Q3 2024 | -$4.4M | +$5.3M |
| Q2 2024 | -$5.7M | +$12.8M |
| Q3 2023 | -$9.7M | +$11.3M |
VERU has burned cash in almost every quarter: −$26M over the past year, against −$29M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over VERU on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
VERU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +57% | +8.4M shares |
| 3 years | +161% | +14.2M shares |
| 5 years | +189% | +15.1M shares |
| Available history | +264% | +16.7M shares |
VERU has 23M diluted shares, up 57% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
VERU Net Leverage
VERU's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
VERU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.7 | Neutral |
| Stochastic | 9.7 | Oversold |
VERU's weekly RSI is 39 (neutral) and its Stochastic is 10 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
VERU PE vs Healthcare Sector
VERU has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over VERU on trend strength, trading above more of its moving averages.
VERU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.31 | 8.2% below |
| 20 week MA | $2.45 | 13% below |
| 50 week MA | $2.47 | 14% below |
| 100 week MA | $3.78 | 44% below |
| 200 week MA | $7.98 | 73% below |
VERU is in a downtrend: it's below all five of its weekly moving averages, and 73% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
VERU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $30.3 | $86.7 | +186% |
| 2021 | $86.7 | $62.9 | -27% |
| 2022 | $62.9 | $50.5 | -20% |
| 2023 | $50.5 | $7.20 | -86% |
| 2024 | $7.20 | $6.76 | -6.1% |
| 2025 | $6.76 | $2.40 | -64% |
| 2026 YTD | $2.40 | $2.12 | -12% |
VERU has the edge over NVO on returns for 2026, with the stronger performance.